erlotinib hydrochloride has been researched along with sesquiterpenes in 5 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (sesquiterpenes) | Trials (sesquiterpenes) | Recent Studies (post-2010) (sesquiterpenes) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 17,489 | 536 | 7,668 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sánchez De Cos Escuín, J | 1 |
| Efferth, T; Gebhart, E; Halatsch, ME; Ramirez, T | 1 |
| Filov, VA; Gershanovich, ML; Imianitov, EN; Stukov, AN | 1 |
| Hann, SS; Huang, HD; Tang, Q; Wu, JJ; Xiao, Q; Xie, J; Yang, XB; Zheng, F | 1 |
| Fan, XX; Huang, JM; Jiang, ZB; Leung, EL; Nie, XW; Shao, L; Sui, X; Wang, J; Wang, WJ; Wang, XR; Wu, QB; Xie, C; Xie, YJ; Xu, C; Yu, LL; Zhang, RN; Zhang, YZ; Zhao, ZM | 1 |
2 review(s) available for erlotinib hydrochloride and sesquiterpenes
| Article | Year |
|---|---|
[New therapeutic targets and strategies in lung cancer].
Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Benzodiazepines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Endothelial Growth Factors; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gefitinib; Humans; Imatinib Mesylate; Imidazoles; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Lymphokines; Metalloendopeptidases; Multicenter Studies as Topic; Piperazines; Polyisoprenyl Phosphates; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Quinolones; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Sesquiterpenes; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
[Problems in the current target therapy of malignancies].
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Azathioprine; Benzamides; Bevacizumab; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Phthalazines; Piperazines; Pyridines; Pyrimidines; Quinazolines; Quinolones; Rituximab; Sesquiterpenes; Sesquiterpenes, Guaiane; Trastuzumab | 2005 |
3 other study(ies) available for erlotinib hydrochloride and sesquiterpenes
| Article | Year |
|---|---|
Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Artesunate; Cell Division; Cell Line; Cluster Analysis; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Nucleic Acid Hybridization; Quinazolines; Sesquiterpenes; Tumor Cells, Cultured | 2004 |
Repression of PDK1- and LncRNA HOTAIR-Mediated EZH2 Gene Expression Contributes to the Enhancement of Atractylenolide 1 and Erlotinib in the Inhibition of Human Lung Cancer Cells.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Animals; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Enhancer of Zeste Homolog 2 Protein; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Lactones; Lung Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; RNA Interference; RNA, Long Noncoding; RNA, Small Interfering; Sesquiterpenes | 2018 |
β-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Ferroptosis; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; RNA, Long Noncoding; Sesquiterpenes | 2023 |